<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111005">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01978665</url>
  </required_header>
  <id_info>
    <org_study_id>2012-004503-13</org_study_id>
    <secondary_id>2012-004503-13</secondary_id>
    <nct_id>NCT01978665</nct_id>
  </id_info>
  <brief_title>The Effect of Prednisone and Solu-Medrol on Physical Exercise in COPD Patients and Inflammatory Response During and After Exercise</brief_title>
  <acronym>COPDprednisone</acronym>
  <official_title>The Effect of Prednisone and Solu-Medrol on Physical Exercise in COPD Patients and the Inflammaroty Response During and After Exercis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <authority>Denmark: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate if there is an effect on exercise performance
      og of the anti inflammatory drugs prednisone and solu-medrol in patints with chronic
      obstructive pulmonary disease(COPD)
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)</study_design>
  <primary_outcome>
    <measure>effect on muscle power</measure>
    <time_frame>jan 2013 to july 2013 (6 months)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>the inflammatory response</measure>
    <time_frame>jan 2013 to july 2013 (6 months)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>vo2max</measure>
    <time_frame>jan 2013 to july 2013 ( 6 months)</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>VO2max</measure>
    <time_frame>jan 2013 until july 2013 (6 months)</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Exercise Performance in Copd Patients</condition>
  <arm_group>
    <arm_group_label>prednisone and Solumedrol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo arm versus prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>solumedrol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo versus solu medrol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <arm_group_label>prednisone and Solumedrol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:FEV1&lt; 60% FEV1/FVC ratio &lt;70 %

          -  able to use a ergometer bike

        Exclusion Criteria: Haemodynamicaly unstable heart conditions

          -  exacerbations before 6 week entry of the study exacerbation during the study period
             treatment with beta blockers malignancy the last 5 years allergi toward IMP
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sebastian Karlsson</last_name>
    <phone>+45 23369715</phone>
    <email>seblundkarlsson@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <state>NV</state>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sebastian Karlsson, MD</last_name>
      <phone>+4531356579</phone>
    </contact>
    <investigator>
      <last_name>Sebastian Karlsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 6, 2013</lastchanged_date>
  <firstreceived_date>November 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Vibeke Backer</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>COPD exercise inflammation prednisone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
